Vifor Pharma

viforpharma.com

Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

National Medtech & Biotech Summit 2024

Conference

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

Related News

VIFOR PHARMA GAINS COMMERCIALISATION RIGHTS FOR CHEMOCENTRYX’S AVACOPAN IN ASIA

Pharmaceutical Technology | February 15, 2017

Swiss-based Vifor Pharma, a Galenica Group company, has gained commercialisation rights for ChemoCentryx’s Avacopan (CCX168) for orphan and rare renal diseases in Asia, including Japan and the Middle East....

AKEBIA AND VIFOR PHARMA ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO PROVIDE VADADUSTAT TO FRESENIUS MEDICAL CARE IN THE U.S. UPON FDA APPROVAL

Pharmacy Choice | June 02, 2017

By a News Reporter-Staff News Editor at Health & Medicine Week Akebia Therapeutics, Inc. (NASDAQ:AKBA) and Vifor Pharma Group. announced they have entered into an exclusive license agreement to sell vadadustat to Fresenius Medical Care dialysis clinics in the United States upon approval by the U.S. Food and Drug Administration (FDA)....

VIFOR PHARMA ACQUIRES PRIORITY REVIEW VOUCHER

Business Wire | February 17, 2020

Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). Vifor Pharma Group is a global speciality pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, h...

Pharma Tech

CSL LIMITED ANNOUNCES TENDER OFFER TO ACQUIRE VIFOR PHARMA LTD

Vifor Pharma Group | December 15, 2021

Global biotechnology leader CSL Limited and Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion. CSL has offered to acquire Vifor Pharma in an all-cash tender offer of US$179.25 per share, payable in U.S. dollars.1 The offer assu...